Debut Plus

₹1,094.85

▲ +5.45 +0.50%

17 Jul 2026

BSE Listed

Jenburkt Pharmaceuticals (524731)

Volume: 216Avg Vol 1W: 409Avg Vol 1M: 1,05052W Range:₹944₹1,364.9
BSE www.jenburkt.com
Key Ratios
Checked just now
Market Cap₹483 Cr
Current Price₹1,094.85
Previous Close₹1,089.4
High / Low (52w)₹1,364.9 / ₹944
Volume216
Avg Vol (1W)409
Avg Vol (1M)1,050
Stock P/E12.85
Book Value₹446.48
Dividend Yield1.9%
ROE17.63%
ROA15.37%
Revenue (TTM)—
Revenue Growth—
Profit Margin20.58%
Total Debt—
Shares Outstanding0 Cr
Face Value—
EPS (TTM)₹85.23
P/B2.45
Debt / Equity0.01
50 DMA₹1,142.1
200 DMA₹1,096.63
Day change+0.50%
Price Chart
₹1,094.85▼ 16.21% · 1Y
₹1342₹95529K
2025-07-17
2026-07-17

20-day avg volume: 1K shares

Pros
  • Healthy return on equity of 17.6%.
  • Pays a dividend yield of 1.9%.
  • Company is almost debt-free.
  • Net profit is growing year over year.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹33 Cr₹41 Cr₹37 Cr₹41 Cr₹36 Cr₹46 Cr₹43 Cr₹45 Cr
EBITDA₹10 Cr₹13 Cr₹10 Cr₹12 Cr₹10 Cr₹14 Cr₹8 Cr₹18 Cr
Net Profit₹7 Cr₹10 Cr₹7 Cr₹9 Cr₹8 Cr₹10 Cr₹6 Cr₹11 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹118 Cr₹126 Cr₹123 Cr₹114 Cr₹129 Cr₹142 Cr₹147 Cr₹158 Cr
EBITDA₹26 Cr₹27 Cr₹22 Cr₹22 Cr₹30 Cr₹33 Cr₹35 Cr₹44 Cr
Net Profit₹17 Cr₹20 Cr₹15 Cr₹17 Cr₹22 Cr₹25 Cr₹26 Cr₹32 Cr
EPS37.543.1432.435.9648.5853.958.8672.65
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹77 Cr₹103 Cr₹104 Cr₹121 Cr₹143 Cr₹142 Cr₹165 Cr₹196 Cr
Total Liabilities₹16 Cr₹25 Cr₹24 Cr₹23 Cr₹26 Cr₹19 Cr₹20 Cr₹24 Cr
Equity₹61 Cr₹77 Cr₹80 Cr₹98 Cr₹117 Cr₹122 Cr₹145 Cr₹172 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹25 Cr₹17 Cr₹25 Cr₹16 Cr₹41 Cr
Investing₹-19 Cr₹-1 Cr₹3 Cr₹-1 Cr₹-17 Cr
Financing₹-1 Cr₹-6 Cr₹-21 Cr₹-7 Cr₹-8 Cr
Free Cash Flow₹25 Cr₹17 Cr₹25 Cr₹16 Cr₹41 Cr
Shareholding
Promoter 46.62% Institutions 0.12% Public 53.26%
Efficiency & Working Capital
ROCE23.2%
Interest Coverage98.6
Dividend Payout—
Debtor Days50 d
Inventory Days21 d
Payable Days20 d
Cash Conversion Cycle52 d
Working Capital Days71 d
Shareholding Details

As of 2026-06-30

Promoter46.6%
FII0%
DII0.1%
Institutions0.1%
Public53.3%
Promoter Pledge0%
No. of Shareholders7,103
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters47.4%47.4%47.2%46.7%46.7%46.7%46.7%46.7%46.7%46.6%46.6%46.6%
FIIs1.4%0%0%0%0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0.1%0.1%0.1%0.1%0.1%0.1%0.1%
Public51.2%52.6%52.8%53.3%53.3%53.2%53.2%53.2%53.2%53.2%53.2%53.3%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders5,8726,0216,3166,4196,6286,9016,9876,7126,8557,1636,9997,103
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Ashish Uttam BhutaShareholding of Promoter and Promoter Group18.1%7,97,607
Bhuta Holdings Private LimitedShareholding of Promoter and Promoter Group14%6,16,128
Kalindi Hemendra BhutaShareholding of Promoter and Promoter Group9.1%3,99,700
Nirmala Vinodkumar DagaPublic Shareholding3.3%1,45,493
Ranjeet Singh SibiaPublic Shareholding1.5%66,244
Optirational Ventures LlpPublic Shareholding1.2%52,836
Bhavika Ashish BhutaShareholding of Promoter and Promoter Group1.2%51,637
Kunti Ketan GalaShareholding of Promoter and Promoter Group1.2%51,278
Rajiv GargPublic Shareholding1.1%47,413
Parshva Kumar DagaPublic Shareholding1.1%46,557
Sushila Paraskumar DagaPublic Shareholding1.1%46,346
Varun DagaPublic Shareholding1%45,450
Kaushik DagaPublic Shareholding1%45,000
Bharath C JainPublic Shareholding1%45,000
Asha Mahesh BhutaShareholding of Promoter and Promoter Group0.9%37,374
Riddhi Haresh ShroffShareholding of Promoter and Promoter Group0.7%32,240
Mahesh Harshad BhutaShareholding of Promoter and Promoter Group0.7%30,486
Jagruti Ketan BhutaShareholding of Promoter and Promoter Group0.5%24,000
Shivani Haresh ShroffShareholding of Promoter and Promoter Group0.4%17,000
Prakash H BhutaShareholding of Promoter and Promoter Group0%0
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Ashish Uttam Bhuta00%2026-06-30
Jagruti Ketan Bhuta00%2026-06-30
Mahesh Harshad Bhuta00%2026-06-30
Kunti Ketan Gala00%2026-06-30
Kalindi Hemendra Bhuta00%2026-06-30
Bhavika Ashish Bhuta00%2026-06-30
Riddhi Haresh Shroff00%2026-06-30
Shivani Haresh Shroff00%2026-06-30
Prakash H Bhuta00%2026-06-30
Asha Mahesh Bhuta00%2026-06-30
Bhuta Holdings Private Limited00%2026-06-30
Rajiv Garg00%2026-06-30
Board of Directors
NameDesignationYear
Ashish U BhutaChairman & Managing Director2025
Dilip H BhutaWhole Time Director & Chief Financial Officer2025
Hina Ravindra MehtaNon Executive & Independent Director2025
Sumit Ajaybhai ThakkarIndependent Director2025
KRISHNAN SUBHARAMANIndependent Director2025
PANKAJ ARUN DANTWALAIndependent Director2025
Ashish R ShahCompany Sec. & Compli. Officer2025
Segments — Geography
RegionRevenueShare
Local₹132 Cr87.4%
Exports₹19 Cr12.6%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹101044
Corporate Actions
TypeDateValueRemark
dividend2025-07-11₹18 (180%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000427
2025000023
2025000404
Company Information
Incorporated1985
ChairmanAshish U Bhuta
AuditorD R Mehta & Associates
Investor Email[email protected]
🌐 www.jenburkt.com ↗

📍 Nirmala Apartment P B No 37396, 93 Jayprakash Road Andheri(W), Mumbai, Maharashtra, 400058

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Sandu Pharmaceuticals Ltd.Vista Pharmaceuticals Ltd.Sun PharmaceuticalTitan Biotech Ltd.Bijoy Hans Ltd.Span Divergent LimitedHikalCaplin Point LaboratoriesFischer Medical VenturesLink Pharma Chem Ltd.Decipher Labs LimitedEmmessar Biotech & NutritAll “52” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search